You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCyclophosphamide
Accession NumberDB00531  (APRD00408)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionPrecursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]
Structure
Thumb
Synonyms
(+-)-Cyclophosphamide
(RS)-Cyclophosphamide
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
Anhydrous cyclophosphamide
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
Ciclofosfamida
Ciclofosfamide
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide anhydrous
Cyclophosphamidum
Cytophosphane
Ledoxina
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
External Identifiers
  • B 518
  • NSC 26271
  • RCRA Waste Number U058
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CyclophosphamideInjection, powder, lyophilized, for solution500 mg/25mLIntravenous; OralBaxter Healthcare Corporation1959-11-16Not applicableUs
CyclophosphamideCapsule50 mg/1OralAvera Mc Kennan Hospital2015-04-23Not applicableUs
CyclophosphamideInjection, powder, lyophilized, for solution1 g/50mLIntravenous; OralBaxter Healthcare Corporation1959-11-16Not applicableUs
CyclophosphamideCapsule25 mg/1OralWest Ward Pharmaceuticals Corp.2013-09-16Not applicableUs
CyclophosphamideInjection, powder, lyophilized, for solution2 g/100mLIntravenous; OralBaxter Healthcare Corporation1959-11-16Not applicableUs
CyclophosphamideCapsule50 mg/1OralWest Ward Pharmaceuticals Corp.2013-09-16Not applicableUs
CyclophosphamideCapsule25 mg/1OralAvera Mc Kennan Hospital2015-08-18Not applicableUs
Cytoxan Pws for Inj 1000mg/vialPowder, for solution1000 mgIntravenousBristol Myers Squibb Canada1990-12-312008-10-17Canada
Cytoxan Pws for Inj 2000mg/vialPowder, for solution2000 mgIntravenousBristol Myers Squibb Canada1990-12-312008-10-17Canada
Cytoxan Tab 25mgTablet25 mgOralBristol Myers Squibb Canada1977-12-312008-11-21Canada
Cytoxan Tab 50mgTablet50 mgOralBristol Myers Squibb Canada1976-12-312009-01-22Canada
Procytox 1000mg/vialPowder, for solution1000 mgIntravenousBaxter Corporation2003-11-18Not applicableCanada
Procytox 2000mg/vialPowder, for solution2000 mgIntravenousBaxter Corporation2003-11-03Not applicableCanada
Procytox 200mg/vialPowder, for solution200 mgIntravenousBaxter Corporation2000-11-26Not applicableCanada
Procytox 500mg/vialPowder, for solution500 mgIntravenousBaxter Corporation2000-10-26Not applicableCanada
Procytox Pws 500mgPowder, for solution500 mgParenteralCarter Horner Corp.1977-12-312000-11-17Canada
Procytox Tab 25mgTablet25 mgOralBaxter Corporation2000-09-01Not applicableCanada
Procytox Tab 25mgTablet25 mgOralCarter Horner Corp.1973-12-312001-05-22Canada
Procytox Tab 50mgTablet50 mgOralBaxter Corporation2000-08-22Not applicableCanada
Procytox Tablets 50mgTablet50 mgOralCarter Horner Corp.1959-12-312001-05-22Canada
Procytox Vial 1000mgPowder, for solution1 gIntravenousCarter Horner Corp.1966-12-312001-05-22Canada
Procytox Vial 200mgPowder, for solution200 mgIntravenousCarter Horner Corp.1959-12-312000-11-26Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CyclophosphamideInjection, powder, for solution2 g/100mLIntravenous; OralBaxter Healthcare Corporation2008-05-21Not applicableUs
CyclophosphamideInjection, powder, for solution2 g/100mLIntravenous; OralBaxter Healthcare Corporation2008-05-21Not applicableUs
CyclophosphamideTablet25 mg/1OralRoxane Laboratories, Inc.1999-08-172016-07-11Us
CyclophosphamideTablet50 mg/1OralPhysicians Total Care, Inc.1999-08-17Not applicableUs
CyclophosphamideInjection, powder, for solution2 g/100mLIntravenous; OralBaxter Healthcare Corporation2008-05-21Not applicableUs
CyclophosphamideInjection, powder, for solution500 mg/25mLIntravenous; OralBaxter Healthcare Corporation2008-05-21Not applicableUs
CyclophosphamideTablet50 mg/1OralRoxane Laboratories, Inc.1999-08-172016-07-11Us
CyclophosphamideInjection, powder, for solution500 mg/25mLIntravenous; OralSandoz Inc.2014-10-31Not applicableUs
CyclophosphamideTablet25 mg/1OralPhysicians Total Care, Inc.1999-08-17Not applicableUs
CyclophosphamideInjection, powder, for solution500 mg/25mLIntravenous; OralBaxter Healthcare Corporation2008-05-21Not applicableUs
CyclophosphamideInjection, powder, for solution1 g/50mLIntravenous; OralBaxter Healthcare Corporation2008-05-21Not applicableUs
CyclophosphamideInjection, powder, for solution500 mg/25mLIntravenous; OralBaxter Healthcare Corporation2008-05-21Not applicableUs
CyclophosphamideInjection, powder, for solution1 g/50mLIntravenous; OralSandoz Inc.2014-10-31Not applicableUs
CyclophosphamideInjection, powder, for solution500 mg/25mLIntravenous; OralBaxter Healthcare Corporation2008-05-21Not applicableUs
CyclophosphamideInjection, powder, for solution1 g/50mLIntravenous; OralBaxter Healthcare Corporation2008-05-21Not applicableUs
CyclophosphamideInjection, powder, for solution2 g/100mLIntravenous; OralBaxter Healthcare Corporation2008-05-21Not applicableUs
CyclophosphamideInjection, powder, for solution1 g/50mLIntravenous; OralBaxter Healthcare Corporation2008-05-21Not applicableUs
CyclophosphamideInjection, powder, for solution2 g/100mLIntravenous; OralSandoz Inc.2014-10-31Not applicableUs
CyclophosphamideInjection, powder, for solution1 g/50mLIntravenous; OralBaxter Healthcare Corporation2008-05-21Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CytoxanBristol-Myers Squibb
EndoxanActavis
NeosarNot Available
ProcytoxBaxter
RevimmuneNot Available
SendoxanBaxter
Brand mixtures
NameLabellerIngredients
Procytox for Injection 2000mg Pws IVCarter Horner Corp.
Salts
Name/CASStructureProperties
Cyclophosphamide monohydrate
6055-19-2
Thumb
  • InChI Key: PWOQRKCAHTVFLB-UHFFFAOYSA-N
  • Monoisotopic Mass: 278.0353848
  • Average Mass: 279.1
DBSALT001814
Categories
UNII6UXW23996M
CAS number50-18-0
WeightAverage: 261.086
Monoisotopic: 260.02481966
Chemical FormulaC7H15Cl2N2O2P
InChI KeyCMSMOCZEIVJLDB-UHFFFAOYSA-N
InChI
InChI=1S/C7H15Cl2N2O2P/c8-2-5-11(6-3-9)14(12)10-4-1-7-13-14/h1-7H2,(H,10,12)
IUPAC Name
2-[bis(2-chloroethyl)amino]-1,3,2λ⁵-oxazaphosphinan-2-one
SMILES
ClCCN(CCCl)P1(=O)NCCCO1
Pharmacology
IndicationCyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
Structured Indications
PharmacodynamicsCyclophosphamide is an antineoplastic in the class of alkylating agents and is used to treat various forms of cancer. Alkylating agents are so named because of their ability to add alkyl groups to many electronegative groups under conditions present in cells. They stop tumor growth by cross-linking guanine bases in DNA double-helix strands - directly attacking DNA. This makes the strands unable to uncoil and separate. As this is necessary in DNA replication, the cells can no longer divide. In addition, these drugs add methyl or other alkyl groups onto molecules where they do not belong which in turn inhibits their correct utilization by base pairing and causes a miscoding of DNA. Alkylating agents are cell cycle-nonspecific. Alkylating agents work by three different mechanisms all of which achieve the same end result - disruption of DNA function and cell death.
Mechanism of actionAlkylating agents work by three different mechanisms: 1) attachment of alkyl groups to DNA bases, resulting in the DNA being fragmented by repair enzymes in their attempts to replace the alkylated bases, preventing DNA synthesis and RNA transcription from the affected DNA, 2) DNA damage via the formation of cross-links (bonds between atoms in the DNA) which prevents DNA from being separated for synthesis or transcription, and 3) the induction of mispairing of the nucleotides leading to mutations.
TargetKindPharmacological actionActionsOrganismUniProt ID
DNANucleotideyes
cross-linking/alkylation
Humannot applicabledetails
Related Articles
AbsorptionAfter oral administration, peak concentrations occur at one hour.
Volume of distribution

30-50 L

Protein binding20% of cyclophosphamide is protein bound with no dose dependent changes. Some metabolites are protein bound to an extent greater than 60%.
Metabolism

Metabolism and activation occurs at the liver. 75% of the drug is activated by cytochrome P450 isoforms, CYP2A6, 2B6, 3A4, 3A5, 2C9, 2C18, and 2C19. The CYP2B6 isoform is the enzyme with the highest 4-hydroxylase activity. Cyclophosphamide undergoes activation to eventually form active metabolites, phosphoramide mustard and acrolein. Cyclophosphamide appears to induce its own metabolism which results in an overall increase in clearance, increased formation of 4-hydroxyl metabolites, and shortened t1/2 values following repeated administration.

SubstrateEnzymesProduct
Cyclophosphamide
4-HydroxycyclophosphamideDetails
Cyclophosphamide
Dechloroethyl cyclophosphamideDetails
Cyclophosphamide
ChloroacetaldehydeDetails
4-Hydroxycyclophosphamide
4-KetocyclophosphamideDetails
4-Hydroxycyclophosphamide
Not Available
AldophosphamideDetails
Aldophosphamide
Not Available
CarboxyphosphamideDetails
Aldophosphamide
AlcophosphamideDetails
Aldophosphamide
CarboxyphosphamideDetails
Carboxyphosphamide
Not Available
Nornitrogen mustardDetails
Aldophosphamide
Not Available
AcroleinDetails
Acrolein
Acrylic AcidDetails
Aldophosphamide
Not Available
Phosphoramide MustardDetails
Phosphoramide Mustard
Not Available
Phosphoramide AziridiniumDetails
Route of eliminationCyclophosphamide is eliminated primarily in the form of metabolites. 10-20% is excreted unchanged in the urine and 4% is excreted in the bile following IV administration.
Half life3-12 hours
Clearance

Total body clearance = 63 ± 7.6 L/kg.

ToxicityAdverse reactions reported most often include neutropenia, febrile neutropenia, fever, alopecia, nausea, vomiting, and diarrhea.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Cyclophosphamide Action PathwayDrug actionSMP00447
Cyclophosphamide Metabolism PathwayDrug metabolismSMP00604
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
Cytochrome P450 3A4
Gene symbol: CYP3A4
UniProt: P08684
rs2740574 CYP3A4 *1BG AllelleDecreased activation of cyclophosphamide most likely contributing to worse disease free survival in adjuvant chemotherapy for node-positive breast cancer20459744
Cytochrome P450 2B6
Gene symbol: CYP2B6
UniProt: P20813
Not AvailableCYP2B6*1GC AllelleDecreased activation of cyclophosphamide contributing to less adverse reactions (leukocytopenia)17502835
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with Cyclophosphamide.Experimental
2-(4-Chlorophenyl)-5-QuinoxalinecarboxamideCyclophosphamide may increase the cardiotoxic activities of 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide.Experimental
2-MethoxyestradiolCyclophosphamide may increase the cardiotoxic activities of 2-Methoxyestradiol.Investigational
3-MethoxybenzamideCyclophosphamide may increase the cardiotoxic activities of 3-Methoxybenzamide.Experimental
3,4-DichloroisocoumarinThe risk or severity of adverse effects can be increased when 3,4-Dichloroisocoumarin is combined with Cyclophosphamide.Experimental
3,4-Dihydroxybenzoic AcidCyclophosphamide may increase the cardiotoxic activities of 3,4-Dihydroxybenzoic Acid.Experimental
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDEThe risk or severity of adverse effects can be increased when 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE is combined with Cyclophosphamide.Experimental
5,10-Dideazatetrahydrofolic AcidCyclophosphamide may increase the cardiotoxic activities of 5,10-Dideazatetrahydrofolic Acid.Experimental
7-HydroxystaurosporineCyclophosphamide may increase the cardiotoxic activities of 7-Hydroxystaurosporine.Experimental
8-azaguanineCyclophosphamide may increase the cardiotoxic activities of 8-azaguanine.Experimental
9-(2-phosphonylmethoxyethyl)-2,6-diaminopurineCyclophosphamide may increase the cardiotoxic activities of 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine.Investigational
AbirateroneThe serum concentration of Cyclophosphamide can be increased when it is combined with Abiraterone.Approved
ABT-263Cyclophosphamide may increase the cardiotoxic activities of ABT-263.Investigational
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Cyclophosphamide.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Cyclophosphamide.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Cyclophosphamide.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Cyclophosphamide.Approved, Vet Approved
AclarubicinCyclophosphamide may increase the cardiotoxic activities of Aclarubicin.Investigational
ActeosideCyclophosphamide may increase the cardiotoxic activities of Acteoside.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Cyclophosphamide.Approved
AfimoxifeneCyclophosphamide may increase the cardiotoxic activities of Afimoxifene.Investigational
AfliberceptCyclophosphamide may increase the cardiotoxic activities of Aflibercept.Approved
AlatrofloxacinCyclophosphamide may increase the cardiotoxic activities of Alatrofloxacin.Withdrawn
AlbendazoleCyclophosphamide may increase the cardiotoxic activities of Albendazole.Approved, Vet Approved
AldesleukinCyclophosphamide may increase the cardiotoxic activities of Aldesleukin.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Cyclophosphamide.Experimental
AlemtuzumabCyclophosphamide may increase the cardiotoxic activities of Alemtuzumab.Approved, Investigational
AlitretinoinCyclophosphamide may increase the cardiotoxic activities of Alitretinoin.Approved, Investigational
AllopurinolThe risk or severity of adverse effects can be increased when Allopurinol is combined with Cyclophosphamide.Approved
AlogliptinThe risk or severity of adverse effects can be increased when Alogliptin is combined with Cyclophosphamide.Approved
Alpha-1-proteinase inhibitorThe risk or severity of adverse effects can be increased when Alpha-1-proteinase inhibitor is combined with Cyclophosphamide.Approved
Alpha-DifluoromethylornithineCyclophosphamide may increase the cardiotoxic activities of Alpha-Difluoromethylornithine.Experimental
ALT-110The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with ALT-110.Investigational
AltretamineCyclophosphamide may increase the cardiotoxic activities of Altretamine.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Cyclophosphamide.Approved, Investigational
Amg 386Cyclophosphamide may increase the cardiotoxic activities of Amg 386.Investigational
AminocamptothecinCyclophosphamide may increase the cardiotoxic activities of Aminocamptothecin.Investigational
AminoglutethimideCyclophosphamide may increase the cardiotoxic activities of Aminoglutethimide.Approved
Aminolevulinic acidCyclophosphamide may increase the cardiotoxic activities of Aminolevulinic acid.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Cyclophosphamide.Approved
AmonafideCyclophosphamide may increase the cardiotoxic activities of Amonafide.Investigational
AmprenavirThe risk or severity of adverse effects can be increased when Amprenavir is combined with Cyclophosphamide.Approved
AmrubicinCyclophosphamide may increase the cardiotoxic activities of Amrubicin.Approved, Investigational
AmsacrineCyclophosphamide may increase the cardiotoxic activities of Amsacrine.Approved
AnagrelideCyclophosphamide may increase the cardiotoxic activities of Anagrelide.Approved
AnastrozoleCyclophosphamide may increase the cardiotoxic activities of Anastrozole.Approved, Investigational
AnecortaveCyclophosphamide may increase the cardiotoxic activities of Anecortave.Investigational
annamycinCyclophosphamide may increase the cardiotoxic activities of annamycin.Investigational
Antithrombin III humanThe risk or severity of adverse effects can be increased when Antithrombin III human is combined with Cyclophosphamide.Approved
AnvirzelAnvirzel may decrease the cardiotoxic activities of Cyclophosphamide.Investigational
AP 12009Cyclophosphamide may increase the cardiotoxic activities of AP 12009.Investigational
AP24534Cyclophosphamide may increase the cardiotoxic activities of AP24534.Investigational
ApaziquoneCyclophosphamide may increase the cardiotoxic activities of Apaziquone.Investigational
ApixabanThe risk or severity of adverse effects can be increased when Apixaban is combined with Cyclophosphamide.Approved
AprepitantThe serum concentration of Cyclophosphamide can be increased when it is combined with Aprepitant.Approved, Investigational
AprotininThe risk or severity of adverse effects can be increased when Aprotinin is combined with Cyclophosphamide.Approved, Withdrawn
ArgatrobanThe risk or severity of adverse effects can be increased when Argatroban is combined with Cyclophosphamide.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Cyclophosphamide.Approved, Investigational
ArmodafinilThe metabolism of Cyclophosphamide can be decreased when combined with Armodafinil.Approved, Investigational
Arsenic trioxideCyclophosphamide may increase the cardiotoxic activities of Arsenic trioxide.Approved, Investigational
ArtemetherThe metabolism of Cyclophosphamide can be decreased when combined with Artemether.Approved
ASA404Cyclophosphamide may increase the cardiotoxic activities of ASA404.Investigational
AsparaginaseCyclophosphamide may increase the cardiotoxic activities of Asparaginase.Approved
AsunaprevirThe risk or severity of adverse effects can be increased when Asunaprevir is combined with Cyclophosphamide.Approved, Investigational
AT-101Cyclophosphamide may increase the cardiotoxic activities of AT-101.Investigational
AtazanavirThe risk or severity of adverse effects can be increased when Atazanavir is combined with Cyclophosphamide.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Cyclophosphamide.Approved
AtomoxetineThe metabolism of Cyclophosphamide can be decreased when combined with Atomoxetine.Approved
AxitinibCyclophosphamide may increase the cardiotoxic activities of Axitinib.Approved, Investigational
AzacitidineCyclophosphamide may increase the cardiotoxic activities of Azacitidine.Approved, Investigational
AzathioprineAzathioprine may increase the hepatotoxic activities of Cyclophosphamide.Approved
AZD2171Cyclophosphamide may increase the cardiotoxic activities of AZD2171.Investigational
Azd4547Cyclophosphamide may increase the cardiotoxic activities of Azd4547.Investigational
Azelaic AcidCyclophosphamide may increase the cardiotoxic activities of Azelaic Acid.Approved
BatimastatCyclophosphamide may increase the cardiotoxic activities of Batimastat.Experimental
BcgThe therapeutic efficacy of Bcg can be decreased when used in combination with Cyclophosphamide.Investigational
BelimumabThe risk or severity of adverse effects can be increased when Belimumab is combined with Cyclophosphamide.Approved
BelinostatCyclophosphamide may increase the cardiotoxic activities of Belinostat.Approved, Investigational
BelotecanCyclophosphamide may increase the cardiotoxic activities of Belotecan.Investigational
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Cyclophosphamide.Approved, Investigational
BendamustineCyclophosphamide may increase the cardiotoxic activities of Bendamustine.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Cyclophosphamide.Approved
BenzamidineThe risk or severity of adverse effects can be increased when Benzamidine is combined with Cyclophosphamide.Experimental
BesifloxacinCyclophosphamide may increase the cardiotoxic activities of Besifloxacin.Approved
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Cyclophosphamide.Approved, Vet Approved
BetaxololThe metabolism of Cyclophosphamide can be decreased when combined with Betaxolol.Approved
Betulinic AcidCyclophosphamide may increase the cardiotoxic activities of Betulinic Acid.Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Cyclophosphamide.Approved, Investigational
BexaroteneCyclophosphamide may increase the cardiotoxic activities of Bexarotene.Approved, Investigational
Bgj398Cyclophosphamide may increase the cardiotoxic activities of Bgj398.Investigational
Bi201335The risk or severity of adverse effects can be increased when Bi201335 is combined with Cyclophosphamide.Investigational
BicalutamideCyclophosphamide may increase the cardiotoxic activities of Bicalutamide.Approved
BivalirudinThe risk or severity of adverse effects can be increased when Bivalirudin is combined with Cyclophosphamide.Approved, Investigational
BizelesinCyclophosphamide may increase the cardiotoxic activities of Bizelesin.Investigational
BleomycinCyclophosphamide may increase the cardiotoxic activities of Bleomycin.Approved
BlinatumomabCyclophosphamide may increase the cardiotoxic activities of Blinatumomab.Approved
Bmn 673Cyclophosphamide may increase the cardiotoxic activities of Bmn 673.Investigational
BoceprevirThe risk or severity of adverse effects can be increased when Boceprevir is combined with Cyclophosphamide.Approved
BortezomibCyclophosphamide may increase the cardiotoxic activities of Bortezomib.Approved, Investigational
BosentanThe serum concentration of Cyclophosphamide can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Cyclophosphamide.Approved
Brentuximab vedotinCyclophosphamide may increase the cardiotoxic activities of Brentuximab vedotin.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Cyclophosphamide.Approved, Investigational
BroxuridineCyclophosphamide may increase the cardiotoxic activities of Broxuridine.Investigational
Bryostatin 1Cyclophosphamide may increase the cardiotoxic activities of Bryostatin 1.Investigational
BSI-201Cyclophosphamide may increase the cardiotoxic activities of BSI-201.Investigational
BupropionThe metabolism of Cyclophosphamide can be decreased when combined with Bupropion.Approved
BusulfanCyclophosphamide may increase the cardiotoxic activities of Busulfan.Approved, Investigational
Buthionine SulfoximineCyclophosphamide may increase the cardiotoxic activities of Buthionine Sulfoximine.Investigational
CabazitaxelCyclophosphamide may increase the cardiotoxic activities of Cabazitaxel.Approved
CabergolineCyclophosphamide may increase the cardiotoxic activities of Cabergoline.Approved
CabozantinibCyclophosphamide may increase the cardiotoxic activities of Cabozantinib.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Cyclophosphamide.Approved
CaiCyclophosphamide may increase the cardiotoxic activities of Cai.Investigational
CalcipotriolCyclophosphamide may increase the cardiotoxic activities of Calcipotriol.Approved
CamptothecinCyclophosphamide may increase the cardiotoxic activities of Camptothecin.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Cyclophosphamide.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Cyclophosphamide.Experimental
CandoxatrilatThe risk or severity of adverse effects can be increased when Candoxatrilat is combined with Cyclophosphamide.Experimental
CapecitabineCyclophosphamide may increase the cardiotoxic activities of Capecitabine.Approved, Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Cyclophosphamide.Approved
CarbamazepineThe metabolism of Cyclophosphamide can be increased when combined with Carbamazepine.Approved, Investigational
CarboplatinCyclophosphamide may increase the cardiotoxic activities of Carboplatin.Approved
CarfilzomibCyclophosphamide may increase the cardiotoxic activities of Carfilzomib.Approved
CarmofurCyclophosphamide may increase the cardiotoxic activities of Carmofur.Withdrawn
CarmustineCyclophosphamide may increase the cardiotoxic activities of Carmustine.Approved
CatumaxomabCyclophosphamide may increase the cardiotoxic activities of Catumaxomab.Investigational
CB1954Cyclophosphamide may increase the cardiotoxic activities of CB1954.Experimental
CDX-110The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with CDX-110.Investigational
CediranibCyclophosphamide may increase the cardiotoxic activities of Cediranib.Investigational
CelecoxibCyclophosphamide may increase the cardiotoxic activities of Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Cyclophosphamide can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Cyclophosphamide.Withdrawn
CetuximabCyclophosphamide may increase the cardiotoxic activities of Cetuximab.Approved
ChlorambucilCyclophosphamide may increase the cardiotoxic activities of Chlorambucil.Approved
ChloramphenicolThe metabolism of Cyclophosphamide can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChloroquineThe metabolism of Cyclophosphamide can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Cyclophosphamide.Approved, Vet Approved
ChlorotrianiseneCyclophosphamide may increase the cardiotoxic activities of Chlorotrianisene.Withdrawn
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Cyclophosphamide.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Cyclophosphamide.Approved
CholecalciferolThe metabolism of Cyclophosphamide can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
ChymostatinThe risk or severity of adverse effects can be increased when Chymostatin is combined with Cyclophosphamide.Experimental
CilastatinThe risk or severity of adverse effects can be increased when Cilastatin is combined with Cyclophosphamide.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Cyclophosphamide.Approved
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Cyclophosphamide.Approved
CinacalcetThe metabolism of Cyclophosphamide can be decreased when combined with Cinacalcet.Approved
CinoxacinCyclophosphamide may increase the cardiotoxic activities of Cinoxacin.Approved, Withdrawn
CiprofloxacinCyclophosphamide may increase the cardiotoxic activities of Ciprofloxacin.Approved, Investigational
CisplatinCyclophosphamide may increase the cardiotoxic activities of Cisplatin.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Cyclophosphamide.Approved
CladribineCyclophosphamide may increase the cardiotoxic activities of Cladribine.Approved, Investigational
ClarithromycinThe metabolism of Cyclophosphamide can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Cyclophosphamide can be decreased when combined with Clemastine.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Cyclophosphamide.Approved, Illicit
ClofarabineCyclophosphamide may increase the cardiotoxic activities of Clofarabine.Approved, Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Cyclophosphamide.Approved, Investigational
ClomipramineThe metabolism of Cyclophosphamide can be decreased when combined with Clomipramine.Approved, Vet Approved
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Cyclophosphamide.Approved
ClopidogrelThe metabolism of Cyclophosphamide can be decreased when combined with Clopidogrel.Approved, Nutraceutical
clorarabineCyclophosphamide may increase the cardiotoxic activities of clorarabine.Investigational
ClotrimazoleThe metabolism of Cyclophosphamide can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Clozapine.Approved
CobicistatThe serum concentration of Cyclophosphamide can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Cyclophosphamide.Approved
CocaineThe metabolism of Cyclophosphamide can be decreased when combined with Cocaine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Cyclophosphamide.Approved
ConivaptanThe serum concentration of Cyclophosphamide can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Cyclophosphamide.Approved
CordycepinCyclophosphamide may increase the cardiotoxic activities of Cordycepin.Investigational
CrenolanibCyclophosphamide may increase the cardiotoxic activities of Crenolanib.Investigational
CrizotinibCyclophosphamide may increase the cardiotoxic activities of Crizotinib.Approved
CurcuminCyclophosphamide may increase the cardiotoxic activities of Curcumin.Investigational
CyclosporineThe metabolism of Cyclophosphamide can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclosporineCyclophosphamide may increase the immunosuppressive activities of Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateCyclophosphamide may increase the cardiotoxic activities of Cyproterone acetate.Approved, Investigational
CytarabineCyclophosphamide may increase the cardiotoxic activities of Cytarabine.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Cyclophosphamide.Approved
DabrafenibThe serum concentration of Cyclophosphamide can be decreased when it is combined with Dabrafenib.Approved
DacarbazineCyclophosphamide may increase the cardiotoxic activities of Dacarbazine.Approved, Investigational
DactinomycinCyclophosphamide may increase the cardiotoxic activities of Dactinomycin.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Cyclophosphamide.Approved
DaratumumabCyclophosphamide may increase the cardiotoxic activities of Daratumumab.Approved
DarifenacinThe metabolism of Cyclophosphamide can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe risk or severity of adverse effects can be increased when Darunavir is combined with Cyclophosphamide.Approved
DasatinibCyclophosphamide may increase the cardiotoxic activities of Dasatinib.Approved, Investigational
DaunorubicinCyclophosphamide may increase the cardiotoxic activities of Daunorubicin.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Cyclophosphamide.Approved
DecitabineCyclophosphamide may increase the cardiotoxic activities of Decitabine.Approved, Investigational
DeferasiroxThe serum concentration of Cyclophosphamide can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Cyclophosphamide can be decreased when combined with Delavirdine.Approved
Denileukin diftitoxCyclophosphamide may increase the cardiotoxic activities of Denileukin diftitox.Approved, Investigational
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Cyclophosphamide.Approved
DeoxyspergualinCyclophosphamide may increase the cardiotoxic activities of Deoxyspergualin.Investigational
DesipramineThe metabolism of Cyclophosphamide can be decreased when combined with Desipramine.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Cyclophosphamide.Approved
DexamethasoneCyclophosphamide may increase the cardiotoxic activities of Dexamethasone.Approved, Investigational, Vet Approved
DexrazoxaneCyclophosphamide may increase the cardiotoxic activities of Dexrazoxane.Approved, Withdrawn
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Cyclophosphamide.Approved, Illicit, Vet Approved
DienogestCyclophosphamide may increase the cardiotoxic activities of Dienogest.Approved
DiethylstilbestrolCyclophosphamide may increase the cardiotoxic activities of Diethylstilbestrol.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Cyclophosphamide.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Cyclophosphamide.Approved
DihydroergotamineThe metabolism of Cyclophosphamide can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Cyclophosphamide.Illicit
DiindolylmethaneCyclophosphamide may increase the cardiotoxic activities of Diindolylmethane.Investigational
DiltiazemThe metabolism of Cyclophosphamide can be decreased when combined with Diltiazem.Approved
DinutuximabCyclophosphamide may increase the cardiotoxic activities of Dinutuximab.Approved
DiphenhydramineThe metabolism of Cyclophosphamide can be decreased when combined with Diphenhydramine.Approved
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Cyclophosphamide.Approved
DocetaxelCyclophosphamide may increase the cardiotoxic activities of Docetaxel.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Cyclophosphamide.Approved, Investigational, Vet Approved
DoxifluridineCyclophosphamide may increase the cardiotoxic activities of Doxifluridine.Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Cyclophosphamide.Approved, Investigational
DoxorubicinCyclophosphamide may increase the cardiotoxic activities of Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Cyclophosphamide can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Cyclophosphamide can be decreased when combined with Dronedarone.Approved
DuloxetineThe metabolism of Cyclophosphamide can be decreased when combined with Duloxetine.Approved
EcabetCyclophosphamide may increase the cardiotoxic activities of Ecabet.Approved, Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Cyclophosphamide.Approved
efaproxiralCyclophosphamide may increase the cardiotoxic activities of efaproxiral.Investigational
EfavirenzThe serum concentration of Cyclophosphamide can be decreased when it is combined with Efavirenz.Approved, Investigational
EflornithineCyclophosphamide may increase the cardiotoxic activities of Eflornithine.Approved, Withdrawn
EG009Cyclophosphamide may increase the cardiotoxic activities of EG009.Investigational
ElafinThe risk or severity of adverse effects can be increased when Elafin is combined with Cyclophosphamide.Investigational
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Cyclophosphamide.Approved, Investigational
EliglustatThe metabolism of Cyclophosphamide can be decreased when combined with Eliglustat.Approved
ElsamitrucinCyclophosphamide may increase the cardiotoxic activities of Elsamitrucin.Investigational
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Cyclophosphamide.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Cyclophosphamide.Approved
EnalkirenThe risk or severity of adverse effects can be increased when Enalkiren is combined with Cyclophosphamide.Experimental
EndostatinCyclophosphamide may increase the cardiotoxic activities of Endostatin.Investigational
EnoxacinCyclophosphamide may increase the cardiotoxic activities of Enoxacin.Approved
EnrofloxacinCyclophosphamide may increase the cardiotoxic activities of Enrofloxacin.Vet Approved
EntinostatCyclophosphamide may increase the cardiotoxic activities of Entinostat.Investigational
EnzalutamideThe serum concentration of Cyclophosphamide can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Cyclophosphamide.Approved, Investigational
EpirubicinCyclophosphamide may increase the cardiotoxic activities of Epirubicin.Approved
EpofolateCyclophosphamide may increase the cardiotoxic activities of Epofolate.Investigational
Epothilone BCyclophosphamide may increase the cardiotoxic activities of Epothilone B.Experimental, Investigational
EribulinCyclophosphamide may increase the cardiotoxic activities of Eribulin.Approved, Investigational
ErlotinibCyclophosphamide may increase the cardiotoxic activities of Erlotinib.Approved, Investigational
ErythromycinThe metabolism of Cyclophosphamide can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Cyclophosphamide can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe metabolism of Cyclophosphamide can be decreased when combined with Esomeprazole.Approved, Investigational
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Cyclophosphamide.Approved, Investigational, Vet Approved
EstramustineCyclophosphamide may increase the cardiotoxic activities of Estramustine.Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Cyclophosphamide.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Cyclophosphamide.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Cyclophosphamide.Approved, Investigational
EtanidazoleCyclophosphamide may increase the cardiotoxic activities of Etanidazole.Investigational
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Cyclophosphamide.Approved
Ethiodized oilCyclophosphamide may increase the cardiotoxic activities of Ethiodized oil.Approved
Ethyl carbamateCyclophosphamide may increase the cardiotoxic activities of Ethyl carbamate.Withdrawn
EtoposideCyclophosphamide may increase the cardiotoxic activities of Etoposide.Approved
EtravirineThe serum concentration of Cyclophosphamide can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Cyclophosphamide.Approved
ExatecanCyclophosphamide may increase the cardiotoxic activities of Exatecan.Investigational
ExemestaneCyclophosphamide may increase the cardiotoxic activities of Exemestane.Approved, Investigational
exisulindCyclophosphamide may increase the cardiotoxic activities of exisulind.Investigational
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Cyclophosphamide.Approved
FelodipineThe metabolism of Cyclophosphamide can be decreased when combined with Felodipine.Approved, Investigational
FenretinideCyclophosphamide may increase the cardiotoxic activities of Fenretinide.Investigational
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Cyclophosphamide.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Cyclophosphamide.Approved
FiacitabineCyclophosphamide may increase the cardiotoxic activities of Fiacitabine.Investigational
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Cyclophosphamide.Approved
FilgrastimThe risk or severity of adverse effects can be increased when Filgrastim is combined with Cyclophosphamide.Approved
FingolimodCyclophosphamide may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FlavopiridolCyclophosphamide may increase the cardiotoxic activities of Flavopiridol.Experimental, Investigational
FleroxacinCyclophosphamide may increase the cardiotoxic activities of Fleroxacin.Approved
FloxuridineCyclophosphamide may increase the cardiotoxic activities of Floxuridine.Approved
FluconazoleThe metabolism of Cyclophosphamide can be decreased when combined with Fluconazole.Approved
FludarabineCyclophosphamide may increase the cardiotoxic activities of Fludarabine.Approved
FlumequineCyclophosphamide may increase the cardiotoxic activities of Flumequine.Withdrawn
FluorouracilCyclophosphamide may increase the cardiotoxic activities of Fluorouracil.Approved
FluoxetineThe metabolism of Cyclophosphamide can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlutamideCyclophosphamide may increase the cardiotoxic activities of Flutamide.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Cyclophosphamide.Approved
FluvastatinThe metabolism of Cyclophosphamide can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Cyclophosphamide can be decreased when combined with Fluvoxamine.Approved, Investigational
FormestaneCyclophosphamide may increase the cardiotoxic activities of Formestane.Approved, Investigational, Withdrawn
FormycinCyclophosphamide may increase the cardiotoxic activities of Formycin.Experimental
FosamprenavirThe risk or severity of adverse effects can be increased when Fosamprenavir is combined with Cyclophosphamide.Approved
FosaprepitantThe serum concentration of Cyclophosphamide can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Cyclophosphamide.Approved
FosphenytoinThe metabolism of Cyclophosphamide can be increased when combined with Fosphenytoin.Approved
FotemustineCyclophosphamide may increase the cardiotoxic activities of Fotemustine.Experimental
FulvestrantCyclophosphamide may increase the cardiotoxic activities of Fulvestrant.Approved, Investigational
FumagillinCyclophosphamide may increase the cardiotoxic activities of Fumagillin.Experimental
Fusidic AcidThe serum concentration of Cyclophosphamide can be increased when it is combined with Fusidic Acid.Approved
G17DTThe risk or severity of adverse effects can be increased when Cyclophosphamide is combined with G17DT.Investigational
GabexateThe risk or severity of adverse effects can be increased when Gabexate is combined with Cyclophosphamide.Investigational
Gallium nitrateCyclophosphamide may increase the cardiotoxic activities of Gallium nitrate.Approved, Investigational
GarenoxacinCyclophosphamide may increase the cardiotoxic activities of Garenoxacin.Investigational
GatifloxacinCyclophosphamide may increase the cardiotoxic activities of Gatifloxacin.Approved, Investigational
GefitinibCyclophosphamide may increase the cardiotoxic activities of Gefitinib.Approved, Investigational
GeldanamycinCyclophosphamide may increase the cardiotoxic activities of Geldanamycin.Experimental
GemcitabineCyclophosphamide may increase the cardiotoxic activities of Gemcitabine.Approved
GemfibrozilThe metabolism of Cyclophosphamide can be decreased when combined with Gemfibrozil.Approved
GemifloxacinCyclophosphamide may increase the cardiotoxic activities of Gemifloxacin.Approved, Investigational
Gemtuzumab ozogamicinCyclophosphamide may increase the cardiotoxic activities of Gemtuzumab ozogamicin.Approved, Investigational, Withdrawn
GenisteinCyclophosphamide may increase the cardiotoxic activities of Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with GI-5005.Investigational
Ginsenoside CCyclophosphamide may increase the cardiotoxic activities of Ginsenoside C.Nutraceutical
GM6001The risk or severity of adverse effects can be increased when GM6001 is combined with Cyclophosphamide.Experimental
GoserelinCyclophosphamide may increase the cardiotoxic activities of Goserelin.Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Cyclophosphamide.Approved
GrepafloxacinCyclophosphamide may increase the cardiotoxic activities of Grepafloxacin.Withdrawn
GusperimusCyclophosphamide may increase the cardiotoxic activities of Gusperimus.Investigational
HadacidinCyclophosphamide may increase the cardiotoxic activities of Hadacidin.Experimental
HalofuginoneCyclophosphamide may increase the cardiotoxic activities of Halofuginone.Investigational, Vet Approved
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Cyclophosphamide.Approved
HexestrolCyclophosphamide may increase the cardiotoxic activities of Hexestrol.Withdrawn
HirulogThe risk or severity of adverse effects can be increased when Hirulog is combined with Cyclophosphamide.Experimental
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Cyclophosphamide.Approved, Vet Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Cyclophosphamide.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Cyclophosphamide.Approved
Hydroxyprogesterone caproateCyclophosphamide may increase the cardiotoxic activities of Hydroxyprogesterone caproate.Approved
HydroxyureaCyclophosphamide may increase the cardiotoxic activities of Hydroxyurea.Approved
IbrutinibCyclophosphamide may increase the cardiotoxic activities of Ibrutinib.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Cyclophosphamide.Approved
IdarubicinCyclophosphamide may increase the cardiotoxic activities of Idarubicin.Approved
IdelalisibThe serum concentration of Cyclophosphamide can be increased when it is combined with Idelalisib.Approved
idraparinuxThe risk or severity of adverse effects can be increased when idraparinux is combined with Cyclophosphamide.Investigational
IfosfamideCyclophosphamide may increase the cardiotoxic activities of Ifosfamide.Approved
Il 4Cyclophosphamide may increase the cardiotoxic activities of Il 4.Investigational
ImatinibCyclophosphamide may increase the cardiotoxic activities of Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Cyclophosphamide.Investigational
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Cyclophosphamide.Approved
ImiquimodCyclophosphamide may increase the cardiotoxic activities of Imiquimod.Approved, Investigational
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Cyclophosphamide.Approved
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Cyclophosphamide.Approved
IndinavirThe risk or severity of adverse effects can be increased when Indinavir is combined with Cyclophosphamide.Approved
IndirubinCyclophosphamide may increase the cardiotoxic activities of Indirubin.Investigational
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Cyclophosphamide.Approved, Investigational
INGN 201The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with INGN 225.Investigational
Interferon beta-1aCyclophosphamide may increase the cardiotoxic activities of Interferon beta-1a.Approved, Investigational
Interferon beta-1bCyclophosphamide may increase the cardiotoxic activities of Interferon beta-1b.Approved
IobenguaneCyclophosphamide may increase the cardiotoxic activities of Iobenguane.Approved
IpilimumabCyclophosphamide may increase the cardiotoxic activities of Ipilimumab.Approved
IrbesartanThe metabolism of Cyclophosphamide can be decreased when combined with Irbesartan.Approved, Investigational
IrinotecanCyclophosphamide may increase the cardiotoxic activities of Irinotecan.Approved, Investigational
IrofulvenCyclophosphamide may increase the cardiotoxic activities of Irofulven.Investigational
IsavuconazoniumThe metabolism of Cyclophosphamide can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoflurophateThe risk or severity of adverse effects can be increased when Isoflurophate is combined with Cyclophosphamide.Approved, Withdrawn
IsoniazidThe metabolism of Cyclophosphamide can be decreased when combined with Isoniazid.Approved
IsradipineThe metabolism of Cyclophosphamide can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Cyclophosphamide can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Cyclophosphamide can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Cyclophosphamide.Approved, Vet Approved
IxabepiloneCyclophosphamide may increase the cardiotoxic activities of Ixabepilone.Approved, Investigational
IxazomibCyclophosphamide may increase the cardiotoxic activities of Ixazomib.Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Cyclophosphamide.Approved
KetoconazoleThe metabolism of Cyclophosphamide can be decreased when combined with Ketoconazole.Approved, Investigational
KOS-1584Cyclophosphamide may increase the cardiotoxic activities of KOS-1584.Investigational
L-alanosineCyclophosphamide may increase the cardiotoxic activities of L-alanosine.Investigational
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Cyclophosphamide.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Cyclophosphamide.Approved, Investigational
LanreotideCyclophosphamide may increase the cardiotoxic activities of Lanreotide.Approved
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Cyclophosphamide.Approved, Investigational
LapatinibCyclophosphamide may increase the cardiotoxic activities of Lapatinib.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Cyclophosphamide.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Leflunomide.Approved, Investigational
LenalidomideCyclophosphamide may increase the cardiotoxic activities of Lenalidomide.Approved
LenvatinibCyclophosphamide may increase the cardiotoxic activities of Lenvatinib.Approved
LepirudinThe risk or severity of adverse effects can be increased when Lepirudin is combined with Cyclophosphamide.Approved
LetrozoleCyclophosphamide may increase the cardiotoxic activities of Letrozole.Approved, Investigational
LeuprolideCyclophosphamide may increase the cardiotoxic activities of Leuprolide.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Cyclophosphamide.Approved, Investigational
LevofloxacinCyclophosphamide may increase the cardiotoxic activities of Levofloxacin.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Cyclophosphamide.Approved
LiarozoleCyclophosphamide may increase the cardiotoxic activities of Liarozole.Investigational
LinagliptinThe risk or severity of adverse effects can be increased when Linagliptin is combined with Cyclophosphamide.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Cyclophosphamide.Approved, Investigational
LomefloxacinCyclophosphamide may increase the cardiotoxic activities of Lomefloxacin.Approved
LomustineCyclophosphamide may increase the cardiotoxic activities of Lomustine.Approved
LonidamineCyclophosphamide may increase the cardiotoxic activities of Lonidamine.Approved, Investigational
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Cyclophosphamide.Approved
LopinavirThe risk or severity of adverse effects can be increased when Lopinavir is combined with Cyclophosphamide.Approved
LorcaserinThe metabolism of Cyclophosphamide can be decreased when combined with Lorcaserin.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Cyclophosphamide.Approved
LovastatinThe metabolism of Cyclophosphamide can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Cyclophosphamide can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Cyclophosphamide can be increased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Cyclophosphamide can be decreased when combined with Lumefantrine.Approved
Ly2801653Cyclophosphamide may increase the cardiotoxic activities of Ly2801653.Investigational
LycopeneCyclophosphamide may increase the cardiotoxic activities of Lycopene.Approved
MafosfamideCyclophosphamide may increase the cardiotoxic activities of Mafosfamide.Investigational
MannitolThe serum concentration of Mannitol can be increased when it is combined with Cyclophosphamide.Approved, Investigational
MasitinibCyclophosphamide may increase the cardiotoxic activities of Masitinib.Vet Approved
MasoprocolCyclophosphamide may increase the cardiotoxic activities of Masoprocol.Approved
MaxacalcitolCyclophosphamide may increase the cardiotoxic activities of Maxacalcitol.Approved
MDX-1106Cyclophosphamide may increase the cardiotoxic activities of MDX-1106.Investigational
MebendazoleCyclophosphamide may increase the cardiotoxic activities of Mebendazole.Approved, Vet Approved
MechlorethamineCyclophosphamide may increase the cardiotoxic activities of Mechlorethamine.Approved
MedrogestoneCyclophosphamide may increase the cardiotoxic activities of Medrogestone.Approved
Medroxyprogesterone acetateCyclophosphamide may increase the cardiotoxic activities of Medroxyprogesterone acetate.Approved, Investigational
Megestrol acetateCyclophosphamide may increase the cardiotoxic activities of Megestrol acetate.Approved, Vet Approved
MelphalanCyclophosphamide may increase the cardiotoxic activities of Melphalan.Approved
MequinolCyclophosphamide may increase the cardiotoxic activities of Mequinol.Approved
MercaptopurineCyclophosphamide may increase the cardiotoxic activities of Mercaptopurine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Cyclophosphamide.Withdrawn
MethadoneThe metabolism of Cyclophosphamide can be decreased when combined with Methadone.Approved
MethotrexateCyclophosphamide may increase the cardiotoxic activities of Methotrexate.Approved
MethotrimeprazineThe metabolism of Cyclophosphamide can be decreased when combined with Methotrimeprazine.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Cyclophosphamide.Approved
Methyl aminolevulinateCyclophosphamide may increase the cardiotoxic activities of Methyl aminolevulinate.Approved
MethylprednisoloneCyclophosphamide may increase the cardiotoxic activities of Methylprednisolone.Approved, Vet Approved
MethyltestosteroneCyclophosphamide may increase the cardiotoxic activities of Methyltestosterone.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Cyclophosphamide.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Cyclophosphamide.Approved, Investigational
MGI-114Cyclophosphamide may increase the cardiotoxic activities of MGI-114.Investigational
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Cyclophosphamide.Approved, Illicit
MidostaurinCyclophosphamide may increase the cardiotoxic activities of Midostaurin.Investigational
MifepristoneThe serum concentration of Cyclophosphamide can be increased when it is combined with Mifepristone.Approved, Investigational
MiltefosineCyclophosphamide may increase the cardiotoxic activities of Miltefosine.Approved
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Cyclophosphamide.Approved
MisonidazoleCyclophosphamide may increase the cardiotoxic activities of Misonidazole.Investigational
MitoguazoneCyclophosphamide may increase the cardiotoxic activities of Mitoguazone.Investigational
MitolactolCyclophosphamide may increase the cardiotoxic activities of Mitolactol.Investigational
MitomycinCyclophosphamide may increase the cardiotoxic activities of Mitomycin.Approved
MitotaneThe serum concentration of Cyclophosphamide can be decreased when it is combined with Mitotane.Approved
MitoxantroneCyclophosphamide may increase the cardiotoxic activities of Mitoxantrone.Approved, Investigational
MizoribineCyclophosphamide may increase the cardiotoxic activities of Mizoribine.Investigational
MLN576Cyclophosphamide may increase the cardiotoxic activities of MLN576.Investigational
MoclobemideThe metabolism of Cyclophosphamide can be decreased when combined with Moclobemide.Approved
ModafinilThe serum concentration of Cyclophosphamide can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Cyclophosphamide.Approved
MolgramostimCyclophosphamide may increase the cardiotoxic activities of Molgramostim.Investigational
MorphineThe serum concentration of Morphine can be increased when it is combined with Cyclophosphamide.Approved, Investigational
motexafin gadoliniumCyclophosphamide may increase the cardiotoxic activities of motexafin gadolinium.Investigational
MoxifloxacinCyclophosphamide may increase the cardiotoxic activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Cyclophosphamide.Approved, Investigational
Mycophenolic acidCyclophosphamide may increase the cardiotoxic activities of Mycophenolic acid.Approved
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe risk or severity of adverse effects can be increased when N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline is combined with Cyclophosphamide.Experimental
NadololThe serum concentration of Nadolol can be increased when it is combined with Cyclophosphamide.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Cyclophosphamide.Investigational
NafcillinThe serum concentration of Cyclophosphamide can be decreased when it is combined with Nafcillin.Approved
Nalidixic AcidCyclophosphamide may increase the cardiotoxic activities of Nalidixic Acid.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Cyclophosphamide.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Cyclophosphamide.Approved, Vet Approved
NamitecanCyclophosphamide may increase the cardiotoxic activities of Namitecan.Investigational
NatalizumabThe risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Natalizumab.Approved, Investigational
NavitoclaxCyclophosphamide may increase the cardiotoxic activities of Navitoclax.Investigational
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Cyclophosphamide.Investigational
NecitumumabCyclophosphamide may increase the cardiotoxic activities of Necitumumab.Approved
NefazodoneThe metabolism of Cyclophosphamide can be decreased when combined with Nefazodone.Approved, Withdrawn
NelarabineCyclophosphamide may increase the cardiotoxic activities of Nelarabine.Approved, Investigational
NelfinavirThe risk or severity of adverse effects can be increased when Nelfinavir is combined with Cyclophosphamide.Approved
NetupitantThe serum concentration of Cyclophosphamide can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Cyclophosphamide can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Cyclophosphamide can be decreased when combined with Nicardipine.Approved
NicotineThe metabolism of Cyclophosphamide can be decreased when combined with Nicotine.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Cyclophosphamide.Approved
NiguldipineCyclophosphamide may increase the cardiotoxic activities of Niguldipine.Experimental
NilotinibCyclophosphamide may increase the cardiotoxic activities of Nilotinib.Approved, Investigational
NilutamideCyclophosphamide may increase the cardiotoxic activities of Nilutamide.Approved
NimustineCyclophosphamide may increase the cardiotoxic activities of Nimustine.Investigational
NintedanibCyclophosphamide may increase the cardiotoxic activities of Nintedanib.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Cyclophosphamide.Investigational
NivolumabCyclophosphamide may increase the cardiotoxic activities of Nivolumab.Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Cyclophosphamide.Approved
Nk012Cyclophosphamide may increase the cardiotoxic activities of Nk012.Investigational
nocodazoleCyclophosphamide may increase the cardiotoxic activities of nocodazole.Experimental
NolatrexedCyclophosphamide may increase the cardiotoxic activities of Nolatrexed.Investigational
NorfloxacinCyclophosphamide may increase the cardiotoxic activities of Norfloxacin.Approved
ObinutuzumabCyclophosphamide may increase the cardiotoxic activities of Obinutuzumab.Approved
OctreotideCyclophosphamide may increase the cardiotoxic activities of Octreotide.Approved, Investigational
OfatumumabCyclophosphamide may increase the cardiotoxic activities of Ofatumumab.Approved
OfloxacinCyclophosphamide may increase the cardiotoxic activities of Ofloxacin.Approved
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Cyclophosphamide.Approved, Investigational
OlaparibCyclophosphamide may increase the cardiotoxic activities of Olaparib.Approved
Omacetaxine mepesuccinateCyclophosphamide may increase the cardiotoxic activities of Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Cyclophosphamide.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Cyclophosphamide.Approved
OmeprazoleThe metabolism of Cyclophosphamide can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OprelvekinCyclophosphamide may increase the cardiotoxic activities of Oprelvekin.Approved, Investigational
OsimertinibCyclophosphamide may increase the cardiotoxic activities of Osimertinib.Approved
OtamixabanThe risk or severity of adverse effects can be increased when Otamixaban is combined with Cyclophosphamide.Investigational
OuabainOuabain may decrease the cardiotoxic activities of Cyclophosphamide.Approved
OxaliplatinCyclophosphamide may increase the cardiotoxic activities of Oxaliplatin.Approved, Investigational
PaclitaxelCyclophosphamide may increase the cardiotoxic activities of Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Cyclophosphamide can be increased when it is combined with Palbociclib.Approved
PalifosfamideCyclophosphamide may increase the cardiotoxic activities of Palifosfamide.Investigational
PamidronateCyclophosphamide may increase the cardiotoxic activities of Pamidronate.Approved
PanitumumabCyclophosphamide may increase the cardiotoxic activities of Panitumumab.Approved, Investigational
PanobinostatThe serum concentration of Cyclophosphamide can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Cyclophosphamide can be decreased when combined with Pantoprazole.Approved
ParoxetineThe metabolism of Cyclophosphamide can be decreased when combined with Paroxetine.Approved, Investigational
PARP inhibitorCyclophosphamide may increase the cardiotoxic activities of PARP inhibitor.Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Cyclophosphamide.Approved
PazufloxacinCyclophosphamide may increase the cardiotoxic activities of Pazufloxacin.Investigational
PefloxacinCyclophosphamide may increase the cardiotoxic activities of Pefloxacin.Approved
PegaspargaseCyclophosphamide may increase the cardiotoxic activities of Pegaspargase.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Cyclophosphamide can be decreased when it is combined with Peginterferon alfa-2b.Approved
PembrolizumabCyclophosphamide may increase the cardiotoxic activities of Pembrolizumab.Approved
PemetrexedCyclophosphamide may increase the cardiotoxic activities of Pemetrexed.Approved, Investigational
PenclomedineCyclophosphamide may increase the cardiotoxic activities of Penclomedine.Investigational
PentobarbitalThe metabolism of Cyclophosphamide can be increased when combined with Pentobarbital.Approved, Vet Approved
PentostatinPentostatin may increase the cardiotoxic activities of Cyclophosphamide.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Cyclophosphamide.Approved
PertuzumabCyclophosphamide may increase the cardiotoxic activities of Pertuzumab.Approved
PhenobarbitalThe metabolism of Cyclophosphamide can be increased when combined with Phenobarbital.Approved
Phenylacetic acidCyclophosphamide may increase the cardiotoxic activities of Phenylacetic acid.Approved
PhenytoinThe metabolism of Cyclophosphamide can be increased when combined with Phenytoin.Approved, Vet Approved
PhosphoramidonThe risk or severity of adverse effects can be increased when Phosphoramidon is combined with Cyclophosphamide.Experimental
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cyclophosphamide.Approved, Investigational
PioglitazoneThe metabolism of Cyclophosphamide can be decreased when combined with Pioglitazone.Approved, Investigational
PipobromanCyclophosphamide may increase the cardiotoxic activities of Pipobroman.Approved
PirarubicinCyclophosphamide may increase the cardiotoxic activities of Pirarubicin.Investigational
PirfenidoneCyclophosphamide may increase the cardiotoxic activities of Pirfenidone.Investigational
PirlindoleCyclophosphamide may increase the cardiotoxic activities of Pirlindole.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Cyclophosphamide.Approved
PixantroneCyclophosphamide may increase the cardiotoxic activities of Pixantrone.Investigational
PlevitrexedCyclophosphamide may increase the cardiotoxic activities of Plevitrexed.Investigational
PlicamycinCyclophosphamide may increase the cardiotoxic activities of Plicamycin.Approved, Withdrawn
PodofiloxCyclophosphamide may increase the cardiotoxic activities of Podofilox.Approved
PodophyllinCyclophosphamide may increase the cardiotoxic activities of Podophyllin.Approved
polyacrylic acidCyclophosphamide may increase the cardiotoxic activities of polyacrylic acid.Investigational
PolythiazideThe risk or severity of adverse effects can be increased when Polythiazide is combined with Cyclophosphamide.Approved
PomalidomideCyclophosphamide may increase the cardiotoxic activities of Pomalidomide.Approved
PonatinibCyclophosphamide may increase the cardiotoxic activities of Ponatinib.Approved
PorfimerCyclophosphamide may increase the cardiotoxic activities of Porfimer.Approved, Investigational
porfiromycinCyclophosphamide may increase the cardiotoxic activities of porfiromycin.Investigational
PosaconazoleThe metabolism of Cyclophosphamide can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PralatrexateCyclophosphamide may increase the cardiotoxic activities of Pralatrexate.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Cyclophosphamide.Approved
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Cyclophosphamide.Approved
PrednimustineCyclophosphamide may increase the cardiotoxic activities of Prednimustine.Investigational
PrednisoloneCyclophosphamide may increase the cardiotoxic activities of Prednisolone.Approved, Vet Approved
PrednisoneCyclophosphamide may increase the cardiotoxic activities of Prednisone.Approved, Vet Approved
PrimidoneThe metabolism of Cyclophosphamide can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe risk or severity of adverse effects can be increased when Prinomastat is combined with Cyclophosphamide.Investigational
ProcarbazineCyclophosphamide may increase the cardiotoxic activities of Procarbazine.Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Cyclophosphamide.Approved, Vet Approved
PromazineThe metabolism of Cyclophosphamide can be decreased when combined with Promazine.Approved, Vet Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Cyclophosphamide.Approved, Investigational
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Cyclophosphamide.Approved
Purine RibosideCyclophosphamide may increase the cardiotoxic activities of Purine Riboside.Experimental
PuromycinCyclophosphamide may increase the cardiotoxic activities of Puromycin.Experimental
PyrazoloacridineCyclophosphamide may increase the cardiotoxic activities of Pyrazoloacridine.Investigational
PyrimethamineThe metabolism of Cyclophosphamide can be decreased when combined with Pyrimethamine.Approved, Vet Approved
Qlt091001Cyclophosphamide may increase the cardiotoxic activities of Qlt091001.Investigational
QuazepamThe serum concentration of Cyclophosphamide can be increased when it is combined with Quazepam.Approved, Illicit
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Cyclophosphamide.Approved
QuinacrineCyclophosphamide may increase the cardiotoxic activities of Quinacrine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Cyclophosphamide.Approved, Investigational
QuinethazoneThe risk or severity of adverse effects can be increased when Quinethazone is combined with Cyclophosphamide.Approved
QuinidineThe metabolism of Cyclophosphamide can be decreased when combined with Quinidine.Approved
QuinineThe serum concentration of Quinine can be increased when it is combined with Cyclophosphamide.Approved
RabeprazoleThe metabolism of Cyclophosphamide can be decreased when combined with Rabeprazole.Approved, Investigational
Rabies vaccineThe risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Rabies vaccine.Approved
Rabies vaccineThe therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Cyclophosphamide.Approved
RacecadotrilThe risk or severity of adverse effects can be increased when Racecadotril is combined with Cyclophosphamide.Investigational
Radium Ra 223 DichlorideCyclophosphamide may increase the cardiotoxic activities of Radium Ra 223 Dichloride.Approved, Investigational
RaltitrexedCyclophosphamide may increase the cardiotoxic activities of Raltitrexed.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Cyclophosphamide.Approved
RamucirumabCyclophosphamide may increase the cardiotoxic activities of Ramucirumab.Approved, Investigational
RanibizumabCyclophosphamide may increase the cardiotoxic activities of Ranibizumab.Approved
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Cyclophosphamide.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Cyclophosphamide.Approved, Investigational
RanpirnaseCyclophosphamide may increase the cardiotoxic activities of Ranpirnase.Investigational
RegorafenibCyclophosphamide may increase the cardiotoxic activities of Regorafenib.Approved
RemikirenThe risk or severity of adverse effects can be increased when Remikiren is combined with Cyclophosphamide.Approved
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Cyclophosphamide.Approved
ResveratrolCyclophosphamide may increase the cardiotoxic activities of Resveratrol.Experimental, Investigational
Rhodamine 6GCyclophosphamide may increase the cardiotoxic activities of Rhodamine 6G.Experimental
RifabutinThe metabolism of Cyclophosphamide can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Cyclophosphamide can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Cyclophosphamide can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Cyclophosphamide.Approved, Investigational
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Cyclophosphamide.Approved, Investigational
RitonavirThe risk or severity of adverse effects can be increased when Ritonavir is combined with Cyclophosphamide.Approved, Investigational
RituximabCyclophosphamide may increase the cardiotoxic activities of Rituximab.Approved
RivaroxabanThe risk or severity of adverse effects can be increased when Rivaroxaban is combined with Cyclophosphamide.Approved
RoflumilastRoflumilast may increase the immunosuppressive activities of Cyclophosphamide.Approved
RolapitantThe metabolism of Cyclophosphamide can be decreased when combined with Rolapitant.Approved
RomidepsinCyclophosphamide may increase the cardiotoxic activities of Romidepsin.Approved, Investigational
RomiplostimCyclophosphamide may increase the cardiotoxic activities of Romiplostim.Approved
RopiniroleThe metabolism of Cyclophosphamide can be decreased when combined with Ropinirole.Approved, Investigational
RoquinimexCyclophosphamide may increase the cardiotoxic activities of Roquinimex.Investigational
RosiglitazoneThe metabolism of Cyclophosphamide can be decreased when combined with Rosiglitazone.Approved, Investigational
RubitecanCyclophosphamide may increase the cardiotoxic activities of Rubitecan.Investigational
RucaparibCyclophosphamide may increase the cardiotoxic activities of Rucaparib.Investigational
RuxolitinibCyclophosphamide may increase the cardiotoxic activities of Ruxolitinib.Approved
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Cyclophosphamide.Approved, Vet Approved
SalirasibCyclophosphamide may increase the cardiotoxic activities of Salirasib.Investigational
SaquinavirThe risk or severity of adverse effects can be increased when Saquinavir is combined with Cyclophosphamide.Approved, Investigational
SaracatinibCyclophosphamide may increase the cardiotoxic activities of Saracatinib.Investigational
SargramostimThe risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Sargramostim.Approved, Investigational
SatraplatinCyclophosphamide may increase the cardiotoxic activities of Satraplatin.Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Cyclophosphamide.Approved
SecobarbitalThe metabolism of Cyclophosphamide can be increased when combined with Secobarbital.Approved, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Cyclophosphamide.Approved
SeliciclibCyclophosphamide may increase the cardiotoxic activities of Seliciclib.Investigational
SemaxanibCyclophosphamide may increase the cardiotoxic activities of Semaxanib.Investigational
SeocalcitolCyclophosphamide may increase the cardiotoxic activities of Seocalcitol.Experimental
SertralineThe metabolism of Cyclophosphamide can be decreased when combined with Sertraline.Approved
SildenafilThe metabolism of Cyclophosphamide can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Cyclophosphamide.Approved
SiltuximabThe serum concentration of Cyclophosphamide can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe risk or severity of adverse effects can be increased when Simeprevir is combined with Cyclophosphamide.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Cyclophosphamide.Approved
SirolimusCyclophosphamide may increase the cardiotoxic activities of Sirolimus.Approved, Investigational
SitagliptinThe risk or severity of adverse effects can be increased when Sitagliptin is combined with Cyclophosphamide.Approved, Investigational
Sodium phenylbutyrateCyclophosphamide may increase the cardiotoxic activities of Sodium phenylbutyrate.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Cyclophosphamide.Approved
SonidegibCyclophosphamide may increase the cardiotoxic activities of Sonidegib.Approved, Investigational
SonifilanCyclophosphamide may increase the cardiotoxic activities of Sonifilan.Investigational
SorafenibCyclophosphamide may increase the cardiotoxic activities of Sorafenib.Approved, Investigational
SparfloxacinCyclophosphamide may increase the cardiotoxic activities of Sparfloxacin.Approved
Sparfosic acidCyclophosphamide may increase the cardiotoxic activities of Sparfosic acid.Experimental
SparsomycinCyclophosphamide may increase the cardiotoxic activities of Sparsomycin.Experimental
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Cyclophosphamide.Experimental
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Cyclophosphamide.Approved
squalamineCyclophosphamide may increase the cardiotoxic activities of squalamine.Investigational
SRP 299The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with SRP 299.Investigational
SRT501Cyclophosphamide may increase the cardiotoxic activities of SRT501.Investigational
St. John's WortThe serum concentration of Cyclophosphamide can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Cyclophosphamide can be increased when it is combined with Stiripentol.Approved
StreptozocinCyclophosphamide may increase the cardiotoxic activities of Streptozocin.Approved
SuccinylcholineThe serum concentration of Succinylcholine can be increased when it is combined with Cyclophosphamide.Approved
SulfadiazineThe metabolism of Cyclophosphamide can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Cyclophosphamide can be decreased when combined with Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Cyclophosphamide can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulforaphaneCyclophosphamide may increase the cardiotoxic activities of Sulforaphane.Investigational
SulindacCyclophosphamide may increase the cardiotoxic activities of Sulindac.Approved
SunitinibCyclophosphamide may increase the cardiotoxic activities of Sunitinib.Approved, Investigational
SuraminCyclophosphamide may increase the cardiotoxic activities of Suramin.Approved
SwainsonineCyclophosphamide may increase the cardiotoxic activities of Swainsonine.Experimental
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Cyclophosphamide.Approved, Investigational
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Cyclophosphamide.Approved, Investigational
TalaporfinCyclophosphamide may increase the cardiotoxic activities of Talaporfin.Investigational
TamoxifenCyclophosphamide may increase the cardiotoxic activities of Tamoxifen.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Cyclophosphamide.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Cyclophosphamide.Approved
TegafurCyclophosphamide may increase the cardiotoxic activities of Tegafur.Approved
TelaprevirThe risk or severity of adverse effects can be increased when Telaprevir is combined with Cyclophosphamide.Approved
TelithromycinThe metabolism of Cyclophosphamide can be decreased when combined with Telithromycin.Approved
TemafloxacinCyclophosphamide may increase the cardiotoxic activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Cyclophosphamide.Experimental, Investigational
TemoporfinCyclophosphamide may increase the cardiotoxic activities of Temoporfin.Approved
TemozolomideCyclophosphamide may increase the cardiotoxic activities of Temozolomide.Approved, Investigational
TemsirolimusCyclophosphamide may increase the cardiotoxic activities of Temsirolimus.Approved
TeniposideCyclophosphamide may increase the cardiotoxic activities of Teniposide.Approved
TerbinafineThe metabolism of Cyclophosphamide can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TeriflunomideThe metabolism of Cyclophosphamide can be decreased when combined with Teriflunomide.Approved
TestolactoneCyclophosphamide may increase the cardiotoxic activities of Testolactone.Approved
TetrathiomolybdateCyclophosphamide may increase the cardiotoxic activities of Tetrathiomolybdate.Investigational
TezacitabineCyclophosphamide may increase the cardiotoxic activities of Tezacitabine.Investigational
TG4010The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with TG4010.Investigational
ThalidomideCyclophosphamide may increase the cardiotoxic activities of Thalidomide.Approved, Investigational, Withdrawn
ThioridazineThe metabolism of Cyclophosphamide can be decreased when combined with Thioridazine.Approved
ThiorphanThe risk or severity of adverse effects can be increased when Thiorphan is combined with Cyclophosphamide.Experimental
ThiotepaCyclophosphamide may increase the cardiotoxic activities of Thiotepa.Approved
ThymalfasinCyclophosphamide may increase the cardiotoxic activities of Thymalfasin.Approved, Investigational
TiboloneCyclophosphamide may increase the cardiotoxic activities of Tibolone.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Cyclophosphamide.Approved
TiclopidineThe metabolism of Cyclophosphamide can be decreased when combined with Ticlopidine.Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Cyclophosphamide.Approved
TioguanineCyclophosphamide may increase the cardiotoxic activities of Tioguanine.Approved
TipifarnibCyclophosphamide may increase the cardiotoxic activities of Tipifarnib.Investigational
TipranavirThe risk or severity of adverse effects can be increased when Tipranavir is combined with Cyclophosphamide.Approved, Investigational
TirapazamineCyclophosphamide may increase the cardiotoxic activities of Tirapazamine.Investigational
TivozanibCyclophosphamide may increase the cardiotoxic activities of Tivozanib.Investigational
Tnp 470Cyclophosphamide may increase the cardiotoxic activities of Tnp 470.Investigational
TocilizumabThe serum concentration of Cyclophosphamide can be decreased when it is combined with Tocilizumab.Approved
TofacitinibCyclophosphamide may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolbutamideThe metabolism of Cyclophosphamide can be decreased when combined with Tolbutamide.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Cyclophosphamide.Approved
TopiramateThe metabolism of Cyclophosphamide can be decreased when combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Cyclophosphamide.Approved, Investigational
ToremifeneCyclophosphamide may increase the cardiotoxic activities of Toremifene.Approved, Investigational
TositumomabCyclophosphamide may increase the cardiotoxic activities of Tositumomab.Approved
TrabectedinCyclophosphamide may increase the cardiotoxic activities of Trabectedin.Approved, Investigational
TrametinibCyclophosphamide may increase the cardiotoxic activities of Trametinib.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Cyclophosphamide.Approved
TranylcypromineThe metabolism of Cyclophosphamide can be decreased when combined with Tranylcypromine.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Cyclophosphamide.Approved, Investigational
Trastuzumab emtansineCyclophosphamide may increase the cardiotoxic activities of Trastuzumab emtansine.Approved
TreosulfanCyclophosphamide may increase the cardiotoxic activities of Treosulfan.Investigational
TretazicarCyclophosphamide may increase the cardiotoxic activities of Tretazicar.Investigational
TretinoinCyclophosphamide may increase the cardiotoxic activities of Tretinoin.Approved, Investigational, Nutraceutical
TrichlormethiazideThe risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Cyclophosphamide.Approved, Vet Approved
TrifluridineCyclophosphamide may increase the cardiotoxic activities of Trifluridine.Approved
TrilostaneCyclophosphamide may increase the cardiotoxic activities of Trilostane.Approved, Investigational, Vet Approved, Withdrawn
TrimethoprimThe metabolism of Cyclophosphamide can be decreased when combined with Trimethoprim.Approved, Vet Approved
TrimetrexateCyclophosphamide may increase the cardiotoxic activities of Trimetrexate.Approved, Investigational
TriptorelinCyclophosphamide may increase the cardiotoxic activities of Triptorelin.Approved, Vet Approved
TrofosfamideCyclophosphamide may increase the cardiotoxic activities of Trofosfamide.Investigational
TrovafloxacinCyclophosphamide may increase the cardiotoxic activities of Trovafloxacin.Approved, Withdrawn
TroxacitabineCyclophosphamide may increase the cardiotoxic activities of Troxacitabine.Investigational
TTNPBCyclophosphamide may increase the cardiotoxic activities of TTNPB.Experimental
TubercidinCyclophosphamide may increase the cardiotoxic activities of Tubercidin.Experimental
UbenimexCyclophosphamide may increase the cardiotoxic activities of Ubenimex.Experimental
UlinastatinThe risk or severity of adverse effects can be increased when Ulinastatin is combined with Cyclophosphamide.Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Cyclophosphamide.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Cyclophosphamide.Approved
Uracil mustardCyclophosphamide may increase the cardiotoxic activities of Uracil mustard.Approved
VadimezanCyclophosphamide may increase the cardiotoxic activities of Vadimezan.Investigational
Val 083Cyclophosphamide may increase the cardiotoxic activities of Val 083.Investigational
Valproic AcidThe metabolism of Cyclophosphamide can be decreased when combined with Valproic Acid.Approved, Investigational
ValrubicinCyclophosphamide may increase the cardiotoxic activities of Valrubicin.Approved
ValsartanThe metabolism of Cyclophosphamide can be decreased when combined with Valsartan.Approved, Investigational
VandetanibCyclophosphamide may increase the cardiotoxic activities of Vandetanib.Approved
VapreotideCyclophosphamide may increase the cardiotoxic activities of Vapreotide.Approved, Investigational
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Cyclophosphamide.Approved
VeliparibCyclophosphamide may increase the cardiotoxic activities of Veliparib.Investigational
VemurafenibCyclophosphamide may increase the cardiotoxic activities of Vemurafenib.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Cyclophosphamide.Approved
VenlafaxineThe metabolism of Cyclophosphamide can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Cyclophosphamide can be decreased when combined with Verapamil.Approved
VerteporfinCyclophosphamide may increase the cardiotoxic activities of Verteporfin.Approved, Investigational
VesnarinoneCyclophosphamide may increase the cardiotoxic activities of Vesnarinone.Investigational
VildagliptinThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Cyclophosphamide.Approved, Investigational
VinblastineCyclophosphamide may increase the cardiotoxic activities of Vinblastine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Cyclophosphamide.Approved, Investigational
VincristineCyclophosphamide may increase the cardiotoxic activities of Vincristine.Approved, Investigational
VindesineCyclophosphamide may increase the cardiotoxic activities of Vindesine.Approved
VinflunineCyclophosphamide may increase the cardiotoxic activities of Vinflunine.Approved
VinorelbineCyclophosphamide may increase the cardiotoxic activities of Vinorelbine.Approved, Investigational
VintafolideCyclophosphamide may increase the cardiotoxic activities of Vintafolide.Investigational
VismodegibCyclophosphamide may increase the cardiotoxic activities of Vismodegib.Approved
Vitamin ACyclophosphamide may increase the cardiotoxic activities of Vitamin A.Approved, Nutraceutical, Vet Approved
VoriconazoleThe metabolism of Cyclophosphamide can be decreased when combined with Voriconazole.Approved, Investigational
VorinostatCyclophosphamide may increase the cardiotoxic activities of Vorinostat.Approved, Investigational
XimelagatranThe risk or severity of adverse effects can be increased when Ximelagatran is combined with Cyclophosphamide.Approved, Investigational, Withdrawn
Ym150The risk or severity of adverse effects can be increased when Ym150 is combined with Cyclophosphamide.Investigational
ZafirlukastThe metabolism of Cyclophosphamide can be decreased when combined with Zafirlukast.Approved, Investigational
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Cyclophosphamide.Approved
ZiprasidoneThe metabolism of Cyclophosphamide can be decreased when combined with Ziprasidone.Approved
ZorubicinCyclophosphamide may increase the cardiotoxic activities of Zorubicin.Experimental
Food Interactions
  • Drink liberally- 2 to 3 liters/day.
  • Take with food to reduce irritation.
References
Synthesis Reference

Riccardo Dalla-Favera, Alessandro Massimo Gianni, “Retroviral vector capable of transducing the aldehyde dehydrogenase-1 gene and making cells resistant to the chemotherapeutic agent cyclophosphamide and its derivatives and analogs.” U.S. Patent US6268138, issued March, 1999.

US6268138
General References
  1. Brock N: The history of the oxazaphosphorine cytostatics. Cancer. 1996 Aug 1;78(3):542-7. [PubMed:8697402 ]
  2. Brock N: Oxazaphosphorine cytostatics: past-present-future. Seventh Cain Memorial Award lecture. Cancer Res. 1989 Jan 1;49(1):1-7. [PubMed:2491747 ]
External Links
ATC CodesL01AA01
AHFS Codes
  • 10:00.00
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (76.1 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9722
Blood Brain Barrier+0.971
Caco-2 permeable-0.5451
P-glycoprotein substrateNon-substrate0.71
P-glycoprotein inhibitor INon-inhibitor0.779
P-glycoprotein inhibitor IINon-inhibitor0.9797
Renal organic cation transporterNon-inhibitor0.8125
CYP450 2C9 substrateNon-substrate0.7856
CYP450 2D6 substrateNon-substrate0.5884
CYP450 3A4 substrateSubstrate0.5461
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9232
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.9232
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9737
Ames testAMES toxic0.9146
CarcinogenicityNon-carcinogens0.8727
BiodegradationNot ready biodegradable0.9511
Rat acute toxicity3.3855 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.8419
hERG inhibition (predictor II)Non-inhibitor0.8735
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Baxter healthcare corp
  • Baxter healthcare corp anesthesia and critical care
  • Teva parenteral medicines inc
  • Roxane laboratories inc
Packagers
Dosage forms
FormRouteStrength
CapsuleOral25 mg/1
CapsuleOral50 mg/1
Injection, powder, for solutionIntravenous; Oral1 g/50mL
Injection, powder, for solutionIntravenous; Oral2 g/100mL
Injection, powder, for solutionIntravenous; Oral500 mg/25mL
Injection, powder, lyophilized, for solutionIntravenous; Oral1 g/50mL
Injection, powder, lyophilized, for solutionIntravenous; Oral2 g/100mL
Injection, powder, lyophilized, for solutionIntravenous; Oral500 mg/25mL
TabletOral25 mg/1
TabletOral50 mg/1
Powder, for solutionIntravenous1000 mg
Powder, for solutionIntravenous2000 mg
Powder, for solutionIntravenous200 mg
Powder, for solutionIntravenous500 mg
Powder, for solutionIntravenous
Powder, for solutionParenteral500 mg
TabletOral25 mg
TabletOral50 mg
Powder, for solutionIntravenous1 g
Prices
Unit descriptionCostUnit
Cyclophosphamide 500 mg vial37.76USD vial
Cyclophosphamide 100% powder33.66USD g
Cytoxan 500 mg vial15.25USD vial
Cytoxan 50 mg tablet4.14USD tablet
Cyclophosphamide 50 mg tablet3.92USD tablet
Cytoxan 25 mg tablet2.26USD tablet
Cyclophosphamide 25 mg tablet2.09USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point48-49Arnold, H., Brock, N. and Bourseaux, F.; U S . Patent 3,018,302; January 23,1962; assigned to Asta-Werke A.G. Chemische Fabrik (W. Germany).
water solubilitySoluble. 1-5 g/100 mL at 23 °CNot Available
logP0.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility15.1 mg/mLALOGPS
logP0.76ALOGPS
logP0.097ChemAxon
logS-1.2ALOGPS
pKa (Strongest Acidic)12.78ChemAxon
pKa (Strongest Basic)-0.57ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area41.57 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity58.48 m3·mol-1ChemAxon
Polarizability23.72 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (9.91 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-08fr-9470000000-53f4a8ff83c415492e03View in MoNA
1D NMR1H NMR SpectrumNot Available
1D NMR13C NMR SpectrumNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as nitrogen mustard compounds. These are compounds having two beta-haloalkyl groups bound to a nitrogen atom.
KingdomOrganic compounds
Super ClassOrganonitrogen compounds
ClassNitrogen mustard compounds
Sub ClassNot Available
Direct ParentNitrogen mustard compounds
Alternative Parents
Substituents
  • Nitrogen mustard
  • Phosphoric monoester diamide
  • Oxazaphosphinane
  • Organic phosphoric acid derivative
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organochloride
  • Organohalogen compound
  • Alkyl halide
  • Alkyl chloride
  • Aliphatic heteromonocyclic compound
Molecular FrameworkAliphatic heteromonocyclic compounds
External DescriptorsNot Available

Targets

1. DNA
Kind
Nucleotide
Organism
Human
Pharmacological action
yes
Actions
cross-linking/alkylation
General Function:
Used for biological information storage.
Specific Function:
DNA contains the instructions needed for an organism to develop, survive and reproduce.
Molecular Weight:
2.15 x 1012 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Khan O, Middleton MR: The therapeutic potential of O6-alkylguanine DNA alkyltransferase inhibitors. Expert Opin Investig Drugs. 2007 Oct;16(10):1573-84. [PubMed:17922622 ]
  4. Schmidt E, Tony HP, Brocker EB, Kneitz C: Sun-induced life-threatening lupus nephritis. Ann N Y Acad Sci. 2007 Jun;1108:35-40. [PubMed:17893968 ]
  5. Zhang QH, Wu CF, Duan L, Yang JY: Protective effects of total saponins from stem and leaf of Panax ginseng against cyclophosphamide-induced genotoxicity and apoptosis in mouse bone marrow cells and peripheral lymphocyte cells. Food Chem Toxicol. 2008 Jan;46(1):293-302. Epub 2007 Aug 23. [PubMed:17904265 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preiss R, Schmidt R, Baumann F, Hanschmann H, Hauss J, Geissler F, Pahlig H, Ratzewiss B: Measurement of 4-hydroxylation of ifosfamide in human liver microsomes using the estimation of free and protein-bound acrolein and codetermination of keto- and carboxyifosfamide. J Cancer Res Clin Oncol. 2002 Jul;128(7):385-92. Epub 2002 Jun 11. [PubMed:12136253 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preiss R, Schmidt R, Baumann F, Hanschmann H, Hauss J, Geissler F, Pahlig H, Ratzewiss B: Measurement of 4-hydroxylation of ifosfamide in human liver microsomes using the estimation of free and protein-bound acrolein and codetermination of keto- and carboxyifosfamide. J Cancer Res Clin Oncol. 2002 Jul;128(7):385-92. Epub 2002 Jun 11. [PubMed:12136253 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Molecular Weight:
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP2C18
Uniprot ID:
P33260
Molecular Weight:
55710.075 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Ekhart C, Doodeman VD, Rodenhuis S, Smits PH, Beijnen JH, Huitema AD: Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide. Pharmacogenet Genomics. 2008 Jun;18(6):515-23. doi: 10.1097/FPC.0b013e3282fc9766. [PubMed:18496131 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Wang E, Lew K, Barecki M, Casciano CN, Clement RP, Johnson WW: Quantitative distinctions of active site molecular recognition by P-glycoprotein and cytochrome P450 3A4. Chem Res Toxicol. 2001 Dec;14(12):1596-603. [PubMed:11743742 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23